DALLAS — Patients who participated in an intensive lifestyle medicine program before total hip and knee arthroplasty had reduced infection risk and less pain 90 days after surgery compared with those who did not participate in the program.
“This study provides the proof on concept that lifestyle medicine interventions not only helps reduce your metabolic burden, but it also translated into health mitigation risks that are sustainable that we don’t see with other methods,” Heidi Prather, DO, medical director of the Lifestyle Medicine Program at Hospital for Special

Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved a new drug application labeling supplement that allows readministration of iDose TR with a repeat treatment protocol, according to a press release from Glaukos.
With the updated labeling, iDose TR (travoprost intracameral implant) may be readministered more than once in patients with corneal endothelial cell density parameters that demonstrate a healthy cornea.
The decision is supported by positive data from the iDose TR exchange trial, which showed the safety and tolerability of a second

Current U.S. Preventive Services Task Force screening guidelines could exclude more than 60% of patients who develop lung cancer.
Conversely, an age-based approach to screening could save more than 25,000 lives per year.
Ankit Bharat, MD, director of the Canning Thoracic Institute and Harold L. and Margaret N. Method Professor of Surgery at Northwestern University Feinberg School of Medicine, described current guidelines as “outdated and ineffective” with an overreliance on smoking history.
“We must urgently think about making lung cancer screening age-based and offer it to everybody in this

Burdensome health care spending in the United States is a wide-reaching issue that requires multiple solutions, according to an expert.
Adam Gaffney, MD, MPH, an assistant professor of medicine at Harvard Medical School, and colleagues recently published the results of a cohort study evaluating burdensome health care spending over time among individuals in the U.S.
The study, which included 12,645 Medical Expenditure Panel Surveys respondents, revealed that the health care system “imposes cost burdens on a larger share of the population than suggested by cross-sectional analyses,” and that

Fear of needles is one of health care’s most common, and most ignored, barriers.
Millions of people experience anxiety or panic attacks at just the sight of a syringe. Some avoid routine vaccinations or postpone blood tests or IV treatments until symptoms worsen. Many who intend to donate blood never show up, held back by a fear they rarely admit aloud.
This is not only a personal struggle. It is a public health problem, too. Surveys show that young adults often cite needle anxiety as the top reason they do not donate blood. This extends to care in hospitals daily: the child who must be

Antidepressant use prior to traumatic brain injury was not associated with worse short-term outcomes for individuals including mortality, neurosurgical intervention or length of hospital stay, according to data published in Neurology.
“Concern remains that serotonergic antidepressants may worsen outcomes after traumatic brain injury (TBI) by increasing the risk of intracranial bleeding, yet high-quality population-level evidence on this issue has been lacking,” Jussi Posti, MD, PhD, associate professor of neurosurgery at the University of Turku in Finland, told Healio.
Posti and colleagues

Abbreviated dual antiplatelet therapy after percutaneous coronary intervention using third-generation stents remained noninferior vs. 12-month DAPT for non-ST-segment elevation myocardial infarction out to 3 years, researchers reported.
Additionally, patients who were event-free at 1 year but remained on DAPT experienced no difference in ischemic outcomes but higher rates of major bleeding events vs. those who switched to single antiplatelet therapy within a year, according to the long-term results of the HOST-IDEA trial published in eClinicalMedicine.
“This study extends the clinical

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics.
Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution), formerly known as Brimochol PF, achieves effect after around 30 minutes and lasts for up to 10 hours, according to Tenpoint. It is the first dual-agent eye drop approved for the treatment of presbyopia and the fourth topical treatment approved overall, following Vuity (pilocarpine HCl ophthalmic solution 1.25%, AbbVie), Qlosi

More than one-third of patients with cutaneous chronic graft-versus-host disease had a perception of treatment response that differed from their clinicians, according to a study published in JAMA Dermatology.
Chronic graft-versus-host disease (cGVHD) is a systemic disorder where graft cells attack the host’s cells after a transplant procedure. While other organs can be affected, up to 80% of patients with this condition report skin involvement, Healio previously reported.
Determining whether the disease is responding to treatment and yielding better patient outcomes can be a challenge,

Girls who develop polycystic ovary syndrome and metabolic dysfunction-associated steatotic liver disease as adolescents have increased risk for adverse cardiometabolic outcomes as adults, according to study findings.
In an analysis of 148 females who participated in a longitudinal cohort study in Australia, women who were identified as having both PCOS and metabolic dysfunction-associated steatotic liver disease (MASLD) had multiple increased adiposity measures, worsened insulin resistance, lower HDL cholesterol and elevated liver enzymes compared with those without PCOS and MASLD.
Oyekoya T.